Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Article in English | MEDLINE | ID: mdl-27625996

ABSTRACT

Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a leading cause of foodborne illnesses worldwide and is a common serotype linked to hemorrhagic colitis and an important cause of hemolytic uremic syndrome (HUS). Treatment of EHEC O157:H7 infections is complicated, as antibiotics can exacerbate Shiga toxin (Stx) production and lead to more severe symptoms including HUS. To date, no vaccines have been approved for human use, exposing a void in both treatment and prevention of EHEC O157:H7 infections. Previously, our lab has shown success in identifying novel vaccine candidates via bio- and immunoinformatics approaches, which are capable of reducing bacterial colonization in an in vivo model of intestinal colonization. In this study, we further characterized 17 of the identified vaccine candidates at the bioinformatics level and evaluated the protective capacity of the top three candidates when administered as DNA vaccines in our murine model of EHEC O157:H7 colonization. Based on further immunoinformatic predictions, these vaccine candidates were expected to induce neutralizing antibodies in a Th2-skewed immunological response. Immunization of BALB/c mice with two of these candidates resulted in reduced bacterial colonization following EHEC O157:H7 challenge. Additionally, immune sera was shown to prevent bacterial adhesion in vitro to Caco-2 cells. Together, this study provides further validation of our immunoinformatic analyses and identifies promising vaccine candidates against EHEC O157:H7.


Subject(s)
Epitopes/immunology , Escherichia coli Infections/prevention & control , Escherichia coli O157/immunology , Escherichia coli Vaccines/immunology , Vaccines, DNA/immunology , Animals , Antibodies, Bacterial/blood , Bacterial Adhesion/drug effects , Caco-2 Cells , Computational Biology , Epitopes/genetics , Escherichia coli Infections/immunology , Escherichia coli O157/genetics , Escherichia coli Vaccines/administration & dosage , Escherichia coli Vaccines/genetics , Humans , Mice, Inbred BALB C , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics
2.
Curr Opin Infect Dis ; 27(5): 459-64, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25023740

ABSTRACT

PURPOSE OF REVIEW: Colonization of the host epithelia by pathogenic Escherichia coli is influenced by the ability of the bacteria to interact with host surfaces. Because the initial step of an E. coli infection is to adhere, invade, and persist within host cells, some strategies used by intestinal and extraintestinal E. coli to infect host cell are presented. RECENT FINDINGS: This review highlights recent progress understanding how extraintestinal pathogenic E. coli strains express specific adhesins or invasins that allow colonization of the urinary tract or the meninges, while intestinal E. coli strains are able to colonize different regions of the intestinal tract using other specialized adhesins or invasins. Finally, evaluation of different diets and environmental conditions regulating the colonization of these pathogens is discussed. SUMMARY: Discovery of new interactions between pathogenic E. coli and the host epithelial cells unravels the need for more mechanistic studies that can provide new clues regarding how to combat these infections.


Subject(s)
Bacterial Adhesion/immunology , Bacterial Translocation/immunology , Escherichia coli Infections/microbiology , Escherichia coli/isolation & purification , Gastrointestinal Tract/microbiology , Meningitis, Escherichia coli/microbiology , Urinary Tract Infections/microbiology , Adhesins, Escherichia coli , Animals , Blood-Brain Barrier/microbiology , Disease Models, Animal , Endothelium, Vascular/microbiology , Escherichia coli/pathogenicity , Escherichia coli Infections/complications , Escherichia coli Infections/immunology , Extracellular Matrix Proteins , Gastrointestinal Tract/immunology , Gene Expression Regulation, Bacterial , Host-Pathogen Interactions/immunology , Humans , Meningitis, Escherichia coli/immunology , Mice , Urinary Tract Infections/etiology , Urinary Tract Infections/immunology
3.
Infect Immun ; 82(5): 2016-26, 2014 May.
Article in English | MEDLINE | ID: mdl-24595137

ABSTRACT

Enterohemorrhagic Escherichia coli (EHEC) O157:H7 strains are major human food-borne pathogens, responsible for bloody diarrhea and hemolytic-uremic syndrome worldwide. Thus far, there is no vaccine for humans against EHEC infections. In this study, a comparative genomics analysis was performed to identify EHEC-specific antigens useful as potential vaccines. The genes present in both EHEC EDL933 and Sakai strains but absent in nonpathogenic E. coli K-12 and HS strains were subjected to an in silico analysis to identify secreted or surface-expressed proteins. We obtained a total of 65 gene-encoding protein candidates, which were subjected to immunoinformatics analysis. Our criteria of selection aided in categorizing the candidates as high, medium, and low priority. Three members of each group were randomly selected and cloned into pVAX-1. Candidates were pooled accordingly to their priority group and tested for immunogenicity against EHEC O157:H7 using a murine model of gastrointestinal infection. The high-priority (HP) pool, containing genes encoding a Lom-like protein (pVAX-31), a putative pilin subunit (pVAX-12), and a fragment of the type III secretion structural protein EscC (pVAX-56.2), was able to induce the production of EHEC IgG and sIgA in sera and feces. HP candidate-immunized mice displayed elevated levels of Th2 cytokines and diminished cecum colonization after wild-type challenge. Individually tested HP vaccine candidates showed that pVAX-12 and pVAX-56.2 significantly induced Th2 cytokines and production of fecal EHEC sIgA, with pVAX-56.2 reducing EHEC cecum colonization. We describe here a bioinformatics approach able to identify novel vaccine candidates potentially useful for preventing EHEC O157:H7 infections.


Subject(s)
Computational Biology/methods , Enterohemorrhagic Escherichia coli/immunology , Escherichia coli Vaccines/immunology , Genomics/methods , Animals , Cecum/microbiology , Feces/microbiology , Female , Genome, Bacterial , Mice , Mice, Inbred BALB C , Transcriptome
4.
Gut Microbes ; 5(6): 770-4, 2014.
Article in English | MEDLINE | ID: mdl-25621619

ABSTRACT

Enterohemorrhagic Escherichia coli (EHEC) strains are well-documented human pathogens and causative agents of diarrheal episodes and hemorrhagic colitis. The serotype O157:H7 is highly virulent and responsible for both outbreaks and sporadic cases of diarrhea. Because antibiotic treatment is contraindicated against this pathogen, development of a human vaccine could be an effective intervention in public health. In our recent Infection and Immunity paper, we applied integrated approaches of in silico genome wide search combined with bioinformatics tools to identify and test O157 vaccine candidates for their protective effect on a murine model of gastrointestinal infection. Using genomic/immunoinformatic approaches that are further described here, we categorized vaccine candidates as high, medium, and low priorities, and demonstrate that some high priority candidates were able to significantly induce Th2 cytokines and reduce EHEC colonization. Using the STRING database, we have recently evaluated the vaccine candidates and predict functional protein interactions, determining whether correlations exist for the development of a multi-subunit vaccine, targeting different pathways against EHEC O157:H7. The overall approach is designed to screen potential vaccine candidates against EHEC; however, the methodology can be quickly applied to many other intestinal pathogens.


Subject(s)
Escherichia coli Infections/microbiology , Escherichia coli O157/metabolism , Escherichia coli Proteins/metabolism , Escherichia coli Vaccines/metabolism , Genomics/methods , Animals , Computational Biology , Escherichia coli Infections/genetics , Escherichia coli Infections/metabolism , Escherichia coli O157/genetics , Escherichia coli Proteins/genetics , Escherichia coli Vaccines/genetics , Humans , Mice , Protein Interaction Maps , Software
5.
Vaccine ; 31(32): 3229-35, 2013 Jul 11.
Article in English | MEDLINE | ID: mdl-23707170

ABSTRACT

Enterohemorrhagic Escherichia coli (EHEC) strains are food borne pathogens with importance in public health. EHEC colonizes the large intestine and causes diarrhea, hemorrhagic colitis and in some cases, life-threatening hemolytic-uremic syndrome (HUS) due to the production of Shiga toxins (Stx). The lack of effective clinical treatment, sequelae after infection and mortality rate in humans supports the urgent need of prophylactic approaches, such as development of vaccines. Shedding from cattle, the main EHEC reservoir and considered the principal food contamination source, has prompted the development of licensed vaccines that reduce EHEC colonization in ruminants. Although murine models do not fully recapitulate human infection, they are commonly used to evaluate EHEC vaccines and the immune/protective responses elicited in the host. Mice susceptibility differs depending of the EHEC inoculums; displaying different mortality rates and Stx-mediated renal damage. Therefore, several experimental protocols have being pursued in this model to develop EHEC-specific vaccines. Recent candidate vaccines evaluated include those composed of virulence factors alone or as fused-subunits, DNA-based, attenuated bacteria and bacterial ghosts. In this review, we summarize progress in the design and testing of EHEC vaccines and the use of different strategies for the evaluation of novel EHEC vaccines in the murine model.


Subject(s)
Disease Models, Animal , Escherichia coli Infections/prevention & control , Escherichia coli Vaccines/immunology , Animals , Bacterial Secretion Systems/immunology , Cattle , Enterohemorrhagic Escherichia coli/pathogenicity , Escherichia coli Infections/immunology , Escherichia coli Infections/veterinary , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/prevention & control , Humans , Inflammation/immunology , Inflammation/pathology , Mice , Shiga Toxins/immunology , Vaccines, DNA/immunology , Vaccines, Subunit/immunology , Virulence Factors/immunology
6.
IUBMB Life ; 65(5): 462-71, 2013 May.
Article in English | MEDLINE | ID: mdl-23504816

ABSTRACT

Signal Transducer and Activator of Transcription (STATs) regulate various target genes such as cyclin D1, MYC, and BCL2 in nonneuronal cells which contribute towards progression as well as prevention of apoptosis and are involved in differentiation and cell survival. However, in neuronal cells, the role of STATs in the activation and regulation of these target genes and their signaling pathways are still not well established. In this study, a robust cyclin D1 expression was observed following IGF-1 stimulation in SY5Y cells as well as neurospheres. JAK/STAT pathway was shown to be involved in this upregulation. A detailed promoter analysis revealed that the specific STAT involved was STAT5, which acted as a positive regulatory element for cyclin D1 expression. Overexpression studies confirmed increase in cyclin D1 expression in response to STAT5a and STAT5b constructs when compared to dominant-negative STAT5. siRNA targeting STAT5, diminished the cyclin D1 expression, further confirming that STAT5 specifically regulated cyclin D1 in neuronal cells. Together, these findings shed new light on the mechanism of IGF-1 mediated upregulation of cyclin D1 expression in neural cell lines as well as in neural stem cells via the JAK/STAT5 signaling cascade.


Subject(s)
Cyclin D1/genetics , Insulin-Like Growth Factor I/pharmacology , Neurons/drug effects , STAT5 Transcription Factor/metabolism , Signal Transduction/drug effects , Up-Regulation/drug effects , Animals , Blotting, Western , Cell Line, Tumor , Cells, Cultured , Cyclin D1/metabolism , Gene Expression Regulation/genetics , Gene Knockdown Techniques , Humans , Insulin-Like Growth Factor I/metabolism , Janus Kinases/metabolism , Neurons/metabolism , Polymerase Chain Reaction , Protein Binding , Rats , Rats, Sprague-Dawley , STAT5 Transcription Factor/genetics
7.
PLoS One ; 7(2): e30280, 2012.
Article in English | MEDLINE | ID: mdl-22347372

ABSTRACT

BACKGROUND: A series of epidemiologic studies have identified the fungus Alternaria as a major risk factor for asthma. The airway epithelium plays a critical role in the pathogenesis of allergic asthma. These reports suggest that activated airway epithelial cells can produce cytokines such as IL-25, TSLP and IL-33 that induce Th2 phenotype. However the epithelium-derived products that mediate the pro-asthma effects of Alternaria are not well characterized. We hypothesized that exposure of the airway epithelium to Alternaria releasing cytokines that can induce Th2 differentiation. METHODOLOGY/PRINCIPAL FINDING: We used ELISA to measure human and mouse cytokines. Alternaria extract (ALT-E) induced rapid release of IL-18, but not IL-4, IL-9, IL-13, IL-25, IL-33, or TSLP from cultured normal human bronchial epithelial cells; and in the BAL fluids of naïve mice after challenge with ALT-E. Both microscopic and FACS indicated that this release was associated with necrosis of epithelial cells. ALT-E induced much greater IL-18 release compared to 19 major outdoor allergens. Culture of naïve CD4 cells with rmIL-18 induced Th2 differentiation in the absence of IL-4 and STAT6, and this effect was abrogated by disrupting NF- κB p50 or with a NEMO binding peptide inhibitor. CONCLUSION/SIGNIFICANCE: Rapid and specific release of IL-18 from Alternaria-exposed damaged airway epithelial cells can directly initiate Th2 differentiation of naïve CD4(+) T-cells via a unique NF-κB dependent pathway.


Subject(s)
Alternaria/immunology , Cell Differentiation/immunology , Epithelial Cells/immunology , Interleukin-18/metabolism , NF-kappa B/immunology , Respiratory System/microbiology , Th2 Cells/pathology , Animals , Cells, Cultured , Cytokines/analysis , Epithelial Cells/microbiology , Epithelial Cells/pathology , Humans , Interleukin-18/immunology , Mice , Necrosis , Respiratory System/immunology , Respiratory System/pathology , Th2 Cells/immunology
8.
J Biol Chem ; 280(36): 31830-40, 2005 Sep 09.
Article in English | MEDLINE | ID: mdl-15998644

ABSTRACT

Janus kinases (JAK) and signal transducers and activator of transcription (STAT) proteins are activated in response to many cytokines and growth factors and are well studied in the immune system. This study was conducted to examine the role of the JAK/STAT pathway in neurons in response to tumor necrosis factor-alpha (TNFalpha) and insulin-like growth factor-1 (IGF-1), which play a major role during neurodegeneration, and to study their effect on expression of suppressors of cytokine signaling 3 (SOCS-3), belonging to the novel family of feedback regulators of cytokine and growth factor activities. In this report, we showed that TNFalpha is inhibitory to the survival of primary cortical neurons at higher doses and that IGF-1 can rescue TNFalpha-stimulated cell death. We showed that the JAK/STAT pathway is involved in this rescue as tyrphostin AG490, a specific inhibitor of JAK/STAT, completely inhibits cell survival in response to IGF-1. STAT3 gets tyrosine-phosphorylated and translocated to the nucleus in response to IGF-1. Northern blot, semi-quantitative reverse transcription-PCR, and real time PCR experiments demonstrated that the JAK/STAT pathway also up-regulated SOCS-3 mainly in response to IGF-1. SOCS-3 associated with the IGF receptor and blocked further STAT3 activation. To our knowledge, this is the first report that demonstrated the importance of the JAK/STAT pathway and the role of SOCS-3 in the survival of neurons in response to IGF-1. We have subsequently shown that SOCS-3 overexpression, on one hand, leads to neuroblastoma cell death and on the other hand leads to primary cell differentiation, indicating the involvement of SOCS-3 in cell survival and differentiation.


Subject(s)
DNA-Binding Proteins/physiology , Insulin-Like Growth Factor I/physiology , Neurons/metabolism , Protein-Tyrosine Kinases/physiology , Repressor Proteins/physiology , Trans-Activators/physiology , Transcription Factors/physiology , Active Transport, Cell Nucleus/physiology , Animals , Cell Line, Tumor , Cell Survival/physiology , DNA-Binding Proteins/metabolism , Humans , Janus Kinase 1 , Protein Transport/physiology , Protein-Tyrosine Kinases/metabolism , Rats , Rats, Sprague-Dawley , Receptor, IGF Type 1/metabolism , STAT3 Transcription Factor , Signal Transduction/physiology , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins , Trans-Activators/metabolism
9.
J Infect Dis ; 190(8): 1476-80, 2004 Oct 15.
Article in English | MEDLINE | ID: mdl-15378441

ABSTRACT

We report the role of human neutrophil peptide (HNP)-1 as an adjunct to antituberculosis (anti-TB) drugs. The combination of HNP-1, isoniazid, and rifampicin was evaluated against Mycobacterium tuberculosis H(37)Rv in vitro, ex vivo, and in vivo, and synergism was observed on the basis of reductions in minimum inhibitory concentrations (MICs) of these agents. In vitro results revealed >1-log unit reductions even when HNP-1 and anti-TB drugs were used at 1/16 MICs. This combination was also found to be bactericidal against intracellular mycobacteria even at 1/8 MICs of HNP-1 and drugs. HNP-1 used in conjunction with anti-TB drugs resulted in significant clearance of bacterial load from lungs, liver, and spleen of infected, compared with control animals. The effective therapeutic dosage of drugs could be reduced to half by supplementing HNP-1 in the therapeutic schedule. These results clearly suggest that HNP-1 can be used as adjunct chemotherapy with conventional drugs against TB.


Subject(s)
Anti-Infective Agents/pharmacology , Mycobacterium tuberculosis/drug effects , Tuberculosis/drug therapy , alpha-Defensins/pharmacology , Animals , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Antitubercular Agents/pharmacology , Antitubercular Agents/therapeutic use , Cell Line , Disease Models, Animal , Drug Evaluation, Preclinical , Drug Therapy, Combination , Female , Isoniazid/pharmacology , Isoniazid/therapeutic use , Male , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Rifampin/pharmacology , Rifampin/therapeutic use , alpha-Defensins/administration & dosage , alpha-Defensins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...